
    
      Prospective, non-interventional, multicentre study meeting a post-marketing need. The data
      will be collected in all patients who have received at least one infusion of octaplasLG®.

      The duration of follow-up is limited to the duration of treatment with octaplasLG® plus 24 h
      of monitoring after cessation of treatment.

      Characteristics of the use of octaplasLG® (indication for the transfusion, degree of urgency,
      characteristics of plasma infusions, patient characteristics, number of iso-group and/or
      compatible units administered, tolerance criteria (adverse effects), and efficacy criteria
      (for patients with confirmed diagnosis of TTP--time to normalization of platelet count) will
      be collected.
    
  